Holen Sie sich die Stockscreener-App
2.46
0.40%
-0.01
Handel nachbörslich:
2.43
-0.03
-1.22%
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Cash Flow - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics, Inc. $IKT Position Boosted by Kalehua Capital Management LLC - MarketBeat
Inhibikase Therapeutics, Inc. Revenue Breakdown – BOATS:IKT - TradingView
IKT|Inhibikase Therapeutics Inc|Price:2.330| - TradingKey
TradingKey - TradingKey
IKT|Inhibikase Therapeutics Inc|Price:2.355|Chg%:+0.025 - TradingKey
Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RA CAPITAL MANAGEMENT, L.P. Acquires 25 Million Shares in Inhibi - GuruFocus
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation fr - GuruFocus
$Inhibikase Therapeutics (IKT.US)$ - Moomoo
Inhibikase Gains FDA Orphan Drug Status for IKT-001 - TipRanks
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation from FDA - GuruFocus
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - The Manila Times
Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans - Stock Titan
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Frontier tech research, news & data - MLQ.ai
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget
Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan
RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan
IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus
Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility - marketscreener.com
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm
Inhibikase raises $50M to fund PAH program - TipRanks
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Nigeria
Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo
Inhibikase raises $50 million through stock sale to RA Capital - Investing.com
Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat
Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan
Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9%Here's What Happened - MarketBeat
Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn ContinuesEPS Surprise History - dars.gov.et
Inhibikase Therapeutics Inc. (IKT) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
INHIBIKASE THERAPEUTICS INC (IKT) Stock Chart - ChartMill
Inhibikase Therapeutics Inc (NASDAQ: IKT) Share Price, IKT Stock News, IKT Share Price & Updates - Kalkine
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase awards stock options to 7 new hires under inducement plan - Stock Titan
Director at Inhibikase (NASDAQ: IKT) receives 155K stock options grant - Stock Titan
Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike price - Stock Titan
Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections - Stock Titan
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Enterprise value to EBIT forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Inhibikase Therapeutics, Inc. Actuals & Estimates (NASDAQ:IKT) - TradingView
IKT Forecast — Price Target — Prediction for 2027 - TradingView
Inhibikase Therapeutics Inc (IKT) Institutional Confidence - TradingKey
Inhibikase Therapeutics Inc (IKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibikase Therapeutics (IKT) Holds Steady Near Support as Traders Await CatalystDividend Stock Picks - DonanımHaber
0.82%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):